- Hemophilia Insights
- Posts
- Hemophilia Insights
Hemophilia Insights
HealthSpotlight is now AllMyHealth
 | ||||||||||||||||||||
Exciting News! HealthSpotlight is now AllMyHealth Wondering why we have a brand new look? We have exciting news - HealthSpotlight has merged with and rebranded as AllMyHealth. Our shared commitment to supporting rare disease communities with trusted resources and advocacy remains as strong as ever - now under a unified name that reflects our patient-first values. We collaborate with patient support groups to create advocacy materials and amplify community news and events. Want to work with us? Find out more here | ||||||||||||||||||||
Exclusive ReportNew Report Release: A Guide to Nutrition for Patients with Hemophilia We’re excited to share our latest in-depth report. This guide provides practical insights on how nutrition plays a vital role in hemophilia. View the Full ReportThe report is available for free online on the AllMyHealth website. www.allmyhealth.io/reports  | ||||||||||||||||||||
Top StoriesPfizer Ends Beqvez Hemophilia Gene Therapy Pfizer is stopping work on Beqvez, a gene therapy for hemophilia B, due to limited interest from patients and doctors. This decision reflects broader challenges in the hemophilia gene therapy field. Read More →Managing Hemophilia with Inhibitors Living with hemophilia inhibitors means treatments don't work as expected, making bleeding harder to control. This affects daily life and requires specialized care to manage symptoms effectively. Read More → | ||||||||||||||||||||
Latest ResearchRecent advancements in hemophilia treatment, such as gene therapy and bio-engineered molecules, have shown promise in reducing treatment frequency and enhancing the quality of life for patients. These therapies are designed to maintain more consistent levels of blood-clotting proteins, potentially reducing the occurrence of spontaneous bleeding events. Clinical trials are exploring next-generation treatments that could further rebalance the blood's ability to clot. Additionally, new technologies like point-of-care musculoskeletal ultrasound and artificial intelligence are being developed to improve diagnosis and treatment outcomes. Despite these innovations, access to these treatments remains a significant challenge globally, with disparities influenced by socioeconomic factors, race, age, and other variables. To achieve health equity, it's crucial to identify and address these barriers. A collaborative approach between patients and healthcare providers, along with engagement from various stakeholders and support from the pharmaceutical industry, is essential to ensure that all patients with hemophilia can benefit from these emerging therapies (Journal of Blood Medicine, 2025). | ||||||||||||||||||||
Community News
🌟 March is Bleeding Disorders Awareness Month! 
Our Chief Community Engagement Officer, Vic McCarty and our VP of Community Engagement, Kim Williams are at the Emory Pathways Center for a Recruitment Fair. Come out to see them if you are interested learning more about opportunities at Hemophilia of Georgia. 
During the WFH's visit to #Egypt, we saw great progress in hemophilia care, thanks to the Egyptian Hemophilia Society (EHS)’s leadership. Yet, adult and uninsured patients still rely on on-demand treatment offered by WFH Humanitarian Aid. Grifols, an early WFH donor, is expanding access through an innovative public-private partnership to collect plasma in the country following the highest international standards for the benefit of persons with primary deficiency and #BleedingDisorders. Read more: https://bit.ly/4gZh4ko  | ||||||||||||||||||||
Upcoming Events | ||||||||||||||||||||
| ||||||||||||||||||||
Click Here to Join Our CommunityJoin Our Waitlist | ||||||||||||||||||||
More Info 
Add to Calendar 